Information Provided By: 
Fly News Breaks for March 31, 2016
OPK
Mar 31, 2016 | 07:43 EDT
Jefferies analyst Brandon Couillard says the FDA's complete response letter to Opko's Health's New Drug Application for Rayaldee as a treatment for secondary hyperparathyroidism was a surprise. While nonfatal, the analyst believes the setback adds a new level of uncertainty around a key value driver that could weigh on the stock well into the second half of 2016. Couillard has a Hold rating and $11 price target on the shares.
News For OPK From the Last 2 Days
There are no results for your query OPK
